Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose‐limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advance...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Minami, Hironobu, Ando, Yuichi, Ma, Brigette Buig Yue, Hsiang Lee, Jih‐, Momota, Hiroyuki, Fujiwara, Yutaka, Li, Leung, Fukino, Koichi, Ito, Koji, Tajima, Takeshi, Mori, Asuka, Lin, Chia‐Chi
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084670/
https://ncbi.nlm.nih.gov/pubmed/27467121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13022
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi